← Back to Clinical Trials
Recruiting NCT06962072

NCT06962072 Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06962072
Status Recruiting
Phase
Sponsor Amsterdam UMC
Condition Soft Tissue Sarcoma
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2025-04-24
Primary Completion 2028-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Surgical resection with or without radiotherapy and/or chemotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2025-04-24 with a primary completion date of 2028-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to assess body image, health-related quality of life (QoL), and functioning (gait function, joint function, and walking ability) in patients after resection of localized soft tissue sarcoma (STS) of the extremities. A secondary objective is to assess the influence of different variables (e.g., radiotherapy, ethnicity, etc.) on body image, health-related QoL, and functioning. Patients who underwent a surgical resection at the Amsterdam UMC between 2010 and 2021 will be approached to participate in the study. Participants will complete four questionnaires and undergo a physical examination. Additionally, they will have a 3D gait analysis, a 6-minute walk test with gas analysis, and a muscle strength assessment. Furthermore, muscle volume change will be evaluated on pre- versus postoperative MRI scans.

Eligibility Criteria

Inclusion Criteria: * Treated with surgical resection for primary non-metastatic extremity STS at the Amsterdam UMC between 2010-2021. * Being able to visit the Amsterdam UMC, location AMC once or twice. * Pregnant patients must agree to be scheduled 5 months after their pregnancy ends. Exclusion Criteria: * Patients who cannot maintain 6 minutes of walking will be excluded from the 6-minute walk test.

Contact & Investigator

Central Contact

Floortje G.M. Verspoor, MD/PhD

✉ f.g.verspoor@amsterdamumc.nl

📞 +310205669111

Frequently Asked Questions

Who can join the NCT06962072 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Soft Tissue Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06962072 currently recruiting?

Yes, NCT06962072 is actively recruiting participants. Contact the research team at f.g.verspoor@amsterdamumc.nl for enrollment information.

Where is the NCT06962072 trial being conducted?

This trial is being conducted at Amsterdam, Netherlands.

Who is sponsoring the NCT06962072 clinical trial?

NCT06962072 is sponsored by Amsterdam UMC. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology